- Home
- KROS vs TTGT Comparison
KROS vs TTGT Comparison
Compare KROS & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- TTGT
- Stock Information
- Founded
- KROS 2015
- TTGT 1999
- Country
- KROS United States
- TTGT United States
- Employees
- KROS N/A
- TTGT N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- TTGT Telecommunications Equipment
- Sector
- KROS Health Care
- TTGT Telecommunications
- Exchange
- KROS Nasdaq
- TTGT Nasdaq
- Market Cap
- KROS 565.0M
- TTGT 468.3M
- IPO Year
- KROS 2020
- TTGT 2007
- Fundamental
- Price
- KROS $14.52
- TTGT $6.22
- Analyst Decision
- KROS Buy
- TTGT Strong Buy
- Analyst Count
- KROS 14
- TTGT 5
- Target Price
- KROS $20.56
- TTGT $16.40
- AVG Volume (30 Days)
- KROS 413.8K
- TTGT 555.6K
- Earning Date
- KROS 08-06-2025
- TTGT 08-12-2025
- Dividend Yield
- KROS N/A
- TTGT N/A
- EPS Growth
- KROS N/A
- TTGT N/A
- EPS
- KROS 0.47
- TTGT N/A
- Revenue
- KROS $232,844,000.00
- TTGT $387,100,000.00
- Revenue This Year
- KROS $5,390.70
- TTGT $74.06
- Revenue Next Year
- KROS N/A
- TTGT N/A
- P/E Ratio
- KROS $31.11
- TTGT N/A
- Revenue Growth
- KROS 85820.30
- TTGT 50.72
- 52 Week Low
- KROS $9.12
- TTGT $5.55
- 52 Week High
- KROS $72.37
- TTGT $33.08
- Technical
- Relative Strength Index (RSI)
- KROS 56.39
- TTGT 41.21
- Support Level
- KROS $13.78
- TTGT $5.55
- Resistance Level
- KROS $14.67
- TTGT $6.55
- Average True Range (ATR)
- KROS 0.45
- TTGT 0.46
- MACD
- KROS 0.03
- TTGT -0.10
- Stochastic Oscillator
- KROS 82.76
- TTGT 26.59
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.